EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

SGLT2 inhibition improves endothelium‐independent vasodilatory function in type 2 diabetes: A double‐blind, randomized, placebo‐controlled crossover trial

Didde Kidmose Kristensen iD, Frank Holden Mose, Niels Henrik Buus, Camilla Lundgreen Duus, Frederik Husum Mårup, Jesper Nørgaard Bech, Steffen Flindt Nielsen

Diabetes, Obesity and Metabolism · 2025

DOI: 10.1111/dom.16097 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Didde Kidmose Kristensen und 6 weiteren Autor:innen. Beteiligte Einrichtung: University Clinic in Nephrology and Hypertension, Gødstrup Hospital, Herning, Denmark. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Benzhydryl Compounds, Vasodilation, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: The Health Science Research Foundation of Central Denmark Region, Augustinus Fonden, Gødstrup Hospital Research Foundation, Central Denmark Region.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

The objective of this study was to examine the effects of empagliflozin on endothelium‐dependent and endothelium‐independent vasodilatation and systemic hemodynamic parameters and to assess the role of the nitric oxide (NO) system in patients with type 2 diabetes (T2DM). Materials and Methods In this double‐blind, placebo‐controlled cross over trial, patients with T2DM were treated with either empagliflozin 10 mg or matching placebo for 4 weeks. Following a 2‐week washout, participants were crossed over to 4 weeks of the opposite treatment. Forearm blood flow (FBF) was measured after each treatment period using venous occlusion plethysmography. Acetylcholine and sodium nitroprusside (SNP) were infused into the brachial artery to assess endothelium‐dependent and endothelium‐independent vasodilatory function, respectively. Total peripheral resistance, 24‐h blood pressure (BP) and biochemical markers of NO activity were measured as well.

Results

Sixteen participants completed the trial. The mean age was 68 ± 8 years, and 69% were male. The SNP response increased by 21% (geometric mean ratio 1.21, 95% CI: 1.09; 1.33) during treatment with empagliflozin compared to placebo ( p ≤ 0.001), but not during acetylcholine infusion ( p = 0.290). Empagliflozin decreased 24‐h systolic BP by 5 mmHg (95% CI: −9; −1 mmHg) ( p = 0.015), diastolic BP by 2 mmHg (95% CI: −5; 0 mmHg) ( p = 0.029) and systemic vascular resistance by 48 dyn×s/m 5 (95% CI: −94; −1 dyn×s/m 5 ) ( p = 0.044). Furthermore, empagliflozin reduced plasma levels of nitrite and urinary levels of NOx.

Conclusions

Empagliflozin improves endothelium‐independent vasodilation, reduces vascular resistance and lowers 24‐h BP in patients with T2DM, whereas no change in endothelial‐dependent vasodilation was observed.

Trial registration

EU Clinical Trials Register number: 2019‐004303‐12 ( https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004303-12/DK ).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Benzhydryl CompoundsVasodilationSodium-Glucose Transporter 2 InhibitorsGlucosidesEndothelium, VascularDiabetic AngiopathiesHumansDouble-Blind MethodMaleFemaleCross-Over StudiesAgedMiddle AgedBlood PressureNitric OxideVasodilator AgentsForearmVascular ResistanceNitroprussideSodium-Glucose Transporter 2

Stichwörter der Autor:innen

SGLT2 inhibitorcardiovascular diseasedrug mechanismempagliflozinrandomized trialtype 2 diabetes

Substanzen

Benzhydryl CompoundsempagliflozinSodium-Glucose Transporter 2 InhibitorsGlucosidesNitric OxideVasodilator AgentsNitroprussideSLC5A2 protein, humanSodium-Glucose Transporter 2

Autor:innen und Institutionen

  • University Clinic in Nephrology and Hypertension, Gødstrup Hospital, Herning, Denmark.
  • Department of Clinical Medicine, Aarhus University, Aarhus N, Denmark.
  • Department of Renal Medicine, Aarhus University Hospital, Aarhus N, Denmark.

ORCID-Profile: Didde Kidmose Kristensen

Förderung

  • The Health Science Research Foundation of Central Denmark Region
  • Augustinus Fonden
  • Gødstrup Hospital Research Foundation, Central Denmark Region
  • The Medicine Funds of the Danish Regions

Zitieren

APA

Kristensen, D. K., Mose, F. H., Buus, N. H., Duus, C. L., Mårup, F. H., Bech, J. N., & Nielsen, S. F. (2025). SGLT2 inhibition improves endothelium‐independent vasodilatory function in type 2 diabetes: A double‐blind, randomized, placebo‐controlled crossover trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16097

Vancouver

Kristensen DK, Mose FH, Buus NH, Duus CL, Mårup FH, Bech JN, et al. SGLT2 inhibition improves endothelium‐independent vasodilatory function in type 2 diabetes: A double‐blind, randomized, placebo‐controlled crossover trial. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16097

BibTeX
@article{Kristensen2025,
  author = {Kristensen, Didde Kidmose and Mose, Frank Holden and Buus, Niels Henrik and Duus, Camilla Lundgreen and Mårup, Frederik Husum and Bech, Jesper Nørgaard and Nielsen, Steffen Flindt},
  title = {SGLT2 inhibition improves endothelium‐independent vasodilatory function in type 2 diabetes: A double‐blind, randomized, placebo‐controlled crossover trial},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  doi = {10.1111/dom.16097}
}
Kostenlos starten →